Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets

Transfusion

Volumn 55, Issue 3, 2015, Pages 507-521

  Pienimaeki Roemer, Annika ^a   Kuhlmann, Katja ^b   Böttcher, Alfred ^a   Konovalova, Tatiana ^a   Black, Anne ^a   Orsõ, Evelyn ^a   Liebisch, Gerhard ^a   Ahrens, Maike ^b   Eisenacher, Martin ^b   Meyer, Helmut E ^c   Schmitz, Gerd ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CLUSTERIN; LIPID; NANOPARTICLE; PROTEIN; MEMBRANE LIPID; MEMBRANE PROTEIN; PLASMA PROTEIN;

ARTICLE; CELL AGING; CELL COMPOSITION; CELL GRANULE; CELL MEMBRANE; CELL TRACKING; CENTRIFUGATION; CONCENTRATION (PARAMETERS); DENSITY GRADIENT CENTRIFUGATION; EXOSOME; EXTRACELLULAR SPACE; FILTRATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRACELLULAR MEMBRANE; LIPID RAFT; LIPIDOMICS; MASS SPECTROMETRY; MEMBRANE VESICLE; MITOCHONDRION; PARTICLE SIZE; PLATELET EXTRACELLULAR VESICLE; PROTEIN LOCALIZATION; PROTEOMICS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE LIFESPAN; THROMBOCYTE MEMBRANE; WESTERN BLOTTING; ADULT; BLOOD; BLOOD STORAGE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; ERYTHROCYTE; IMMUNOMAGNETIC SEPARATION; ISOLATION AND PURIFICATION; MEMBRANE MICROPARTICLE; NERVE DEGENERATION; PROCEDURES; THROMBOCYTE; THROMBOCYTOPHERESIS;

ADULT; ALPHA-SYNUCLEIN; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD PROTEINS; BLOTTING, WESTERN; CELL AGING; CELL-DERIVED MICROPARTICLES; CENTRIFUGATION; ERYTHROCYTES; EXOSOMES; FILTRATION; FLOW CYTOMETRY; HUMANS; IMMUNOMAGNETIC SEPARATION; LIPIDS; MASS SPECTROMETRY; MEMBRANE LIPIDS; MEMBRANE PROTEINS; NANOPARTICLES; NERVE DEGENERATION; PLATELET ACTIVATION; PLATELETPHERESIS;

EID: 84924455330     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12874     Document Type: Article

References (94)

1. Burnier L, Fontana P, Kwak BR, et-al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
2. Nomura S, Ozaki Y, Ikeda Y,. Function and role of microparticles in various clinical settings. Thromb Res 2008; 123: 8-23.
3. Suades R, Padro T, Vilahur G, et-al. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012; 108: 1208-1219.
4. Wolf P,. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288.
5. Aatonen M, Gronholm M, Siljander PR,. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012; 38: 102-113.
6. Heijnen HF, Debili N, Vainchencker W, et-al. Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granules. Blood 1998; 91: 2313-2325.
7. Denzer K, Kleijmeer MJ, Heijnen HF, et-al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113 (Pt 19): 3365-3374.
8. Klinger MH,. The storage lesion of platelets: ultrastructural and functional aspects. Ann Hematol 1996; 73: 103-112.
9. Escolar G, White JG,. The platelet open canalicular system: a final common pathway. Blood Cells 1991; 17: 467-485; discussion 486-95.
10. Dean WL, Lee MJ, Cummins TD, et-al. Proteomic and functional characterisation of platelet microparticle size classes. Thromb Haemost 2009; 102: 711-718.
11. Duarte D, Taveira-Gomes T, Sokhatska O, et-al. Increased circulating platelet microparticles as a potential biomarker in asthma. Allergy 2013; 68: 1073-1075.
12. Martin M, de Paz R, Jimenez-Yuste V, et-al. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. Thromb Haemost 2013; 109: 909-919.
13. Garcia BA, Smalley DM, Cho H, et-al. The platelet microparticle proteome. J Proteome Res 2005; 4: 1516-1521.
14. Smalley DM, Root KE, Cho H, et-al. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 2007; 97: 67-80.
15. Capriotti AL, Caruso G, Cavaliere C, et-al. Proteomic characterization of human platelet-derived microparticles. Anal Chim Acta 2013; 776: 57-63.
16. Boing AN, Hau CM, Sturk A, et-al. Platelet microparticles contain active caspase 3. Platelets 2008; 19: 96-103.
17. Jy W, Horstman LL, Wang F, et-al. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb Res 1995; 80: 471-482.
18. Leytin V,. Apoptosis in the anucleate platelet. Blood Rev 2012; 26: 51-63.
19. Vasina EM, Cauwenberghs S, Staudt M, et-al. Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res 2013; 3: 107-123.
20. Pienimaeki-Roemer A, Ruebsaamen K, Boettcher A, et-al. Stored platelets alter glycerophospholipid and sphingolipid species, which are differentially transferred to newly released extracellular vesicles. Transfusion 2012; 53: 612-626.
21. Shantsila E, Kamphuisen PW, Lip GY,. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358-2368.
22. Kalaria RN, Akinyemi R, Ihara M,. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 2012; 322: 141-147.
23. Cordonnier C, van der Flier WM,. Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 2011; 134: 335-344.
24. Olazaran J, Ramos A, Boyano I, et-al. Pattern of and risk factors for brain microbleeds in neurodegenerative dementia. Am J Alzheimers Dis Other Demen 2014; 29: 263-269.
25. Ruebsaamen K, Liebisch G, Boettcher A, et-al. Lipidomic analysis of platelet senescence. Transfusion 2010; 50: 1665-1676.
26. Scherer M, Schmitz G, Liebisch G,. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry. Clin Chem 2009; 55: 1218-1222.
27. Scherer M, Leuthauser-Jaschinski K, Ecker J, et-al. A rapid and quantitative LC-MS/MS method to profile sphingolipids. J Lipid Res 2010; 51: 2001-2011.
28. Scherer M, Schmitz G, Liebisch G,. Simultaneous quantification of cardiolipin, bis(monoacylglycero)phosphate and their precursors by hydrophilic interaction LC-MS/MS including correction of isotopic overlap. Anal Chem 2010; 82: 8794-8799.
29. Liebisch G, Lieser B, Rathenberg J, et-al. High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. Biochim Biophys Acta 2004; 1686: 108-117.
30. Liebisch G, Vizcaino JA, Kofeler H, et-al. Shorthand notation for lipid structures derived from mass spectrometry. J Lipid Res 2013; 54: 1523-1530.
31. Wiese S, Gronemeyer T, Ofman R, et-al. Proteomics characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein correlation profiling. Mol Cell Proteomics 2007; 6: 2045-2057.
32. Cox J, Mann M,. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26: 1367-1372.
33. van der Pol E, Boing AN, Harrison P, et-al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012; 64: 676-705.
34. György B, Modos K, Pallinger E, et-al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood 2011; 117: e39-48.
35. Witwer KW, Buzás EI, Bemis LT, et-al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2013; 2: 20360.
36. Chandler WL,. Microparticle counts in platelet-rich and platelet-free plasma, effect of centrifugation and sample-processing protocols. Blood Coagul Fibrinolysis 2013; 24: 125-132.
37. Keuren JF, Magdeleyns EJ, Govers-Riemslag JW, et-al. Effects of storage-induced platelet microparticles on the initiation and propagation phase of blood coagulation. Br J Haematol 2006; 134: 307-313.
38. Shet AS, Key NS, Hebbel RP,. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 2: 1848-1850.
39. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, et-al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008; 173: 1210-1219.
40. van Beers EJ, Schaap MC, Berckmans RJ, et-al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009; 94: 1513-1519.
41. Lasser C, Eldh M, Lotvall J,. Isolation and characterization of RNA-containing exosomes. J Vis Exp 2012; 59: e3037.
42. Gorgani NN, Easterbrook-Smith SB, Altin JG,. The formation of insoluble immune complexes between ovalbumin and anti-ovalbumin IgG occurs in at least two distinct phases dependent on reactant concentration and ionic strength. Biochim Biophys Acta 1996; 1317: 45-54.
43. Williams JC, Mackman N,. MPs or ICs? Blood 2011; 117: 1101-1102.
44. van der Pol E, Coumans FA, Grootemaat AE, et-al. Particle size distribution of exosomes and microvesicles by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 2014; 12: 1182-1192.
45. Thery C, Ostrowski M, Segura E,. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9: 581-593.
46. Filipe V, Hawe A, Jiskoot W,. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010; 27: 796-810.
47. Fauvel J, Chap H, Roques V, et-al. Biochemical characterization of plasma membranes and intracellular membranes isolated from human platelets using Percoll gradients. Biochim Biophys Acta 1986; 856: 155-164.
48. Biro E, Akkerman JW, Hoek FJ, et-al. The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions. J Thromb Haemost 2005; 3: 2754-2763.
49. Tani M, Ito M, Igarashi Y,. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell Signal 2007; 19: 229-237.
50. Poccia D, Larijani B,. Phosphatidylinositol metabolism and membrane fusion. Biochem J 2009; 418: 233-246.
51. Crescitelli R, Lasser C, Szabo TG, et-al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles 2013; 2.
52. Flaumenhaft R, Dilks JR, Rozenvayn N, et-al. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood 2005; 105: 3879-3887.
53. Lim YA, Hyun BH,. Evaluation of platelet parameters on the ADVIA 120 as the quality indicator for stored platelets. Clin Lab Haematol 2002; 24: 377-384.
54. Wolfs JL, Comfurius P, Rasmussen JT, et-al. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005; 62: 1514-1525.
55. Colombini M,. Membrane channels formed by ceramide. Handb Exp Pharmacol 2013; 215: 109-126.
56. Sentelle RD, Senkal CE, Jiang W, et-al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol 2012; 8: 831-838.
57. Osman C, Voelker DR, Langer T,. Making heads or tails of phospholipids in mitochondria. J Cell Biol 2011; 192: 7-16.
58. Perales Villarroel JP, Figueredo R, Guan Y, et-al. Increased platelet storage time is associated with mitochondrial dysfunction and impaired platelet function. J Surg Res 2013; 184: 422-429.
59. Rajawat YS, Hilioti Z, Bossis I,. Aging: central role for autophagy and the lysosomal degradative system. Ageing Res Rev 2009; 8: 199-213.
60. Mortensen M, Ferguson DJ, Simon AK,. Mitochondrial clearance by autophagy in developing erythrocytes: clearly important, but just how much so? Cell Cycle 2010; 9: 1901-1906.
61. Vidal M, Sainte-Marie J, Philippot JR, et-al. Asymmetric distribution of phospholipids in the membrane of vesicles released during in vitro maturation of guinea pig reticulocytes: evidence precluding a role for "aminophospholipid translocase." J Cell Physiol 1989; 140: 455-462.
62. Tariq Sadiq S, Agranoff D,. Pooling serum samples may lead to loss of potential biomarkers in SELDI-ToF MS proteomic profiling. Proteome Sci 2008; 6: 16.
63. Duyckaerts C, Seilhean D,. Progress in neuropathology changes the understanding of neurodegenerative diseases. Rev Prat 2013; 63: 655-661.
64. Burns MP, Noble WJ, Olm V, et-al. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res 2003; 110: 119-125.
65. Martin-Rehrmann MD, Hoe HS, Capuani EM, et-al. Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain. Neurotox Res 2005; 7: 231-242.
66. Spillantini MG, Crowther RA, Jakes R, et-al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95: 6469-6473.
67. Takeda A, Mallory M, Sundsmo M, et-al. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 1998; 152: 367-372.
68. Wakabayashi K, Yoshimoto M, Tsuji S, et-al. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998; 249: 180-182.
69. Shimizu F, Kanda T,. Disruption of the blood-brain barrier in inflammatory neurological diseases. Brain Nerve 2013; 65: 165-176.
70. Obermeier B, Daneman R, Ransohoff RM,. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013; 19: 1584-1596.
71. Barbour R, Kling K, Anderson JP, et-al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008; 5: 55-59.
72. Abou-Sleiman PM, Healy DG, Wood NW,. Causes of Parkinson's disease: genetics of DJ-1. Cell Tissue Res 2004; 318: 185-188.
73. Hashimoto M, Yoshimoto M, Sisk A, et-al. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 1997; 237: 611-616.
74. Park SM, Jung HY, Kim HO, et-al. Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets. Blood 2002; 100: 2506-2514.
75. Klinger MH,. Inflammation. In:, Michelson AD, editor. Platelets. London: Academic Press; 2002. p. 459-467.
76. Zhang W, Huang W, Jing F,. Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med 2013; 4: 141-147.
77. Biere AL, Ostaszewski B, Stimson ER, et-al. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271: 32916-32922.
78. Li QX, Berndt MC, Bush AI, et-al. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 1994; 84: 133-142.
79. Vignini A, Nanetti L, Moroni C, et-al. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol Aging 2007; 28: 987-994.
80. Sevush S, Jy W, Horstman LL, et-al. Platelet activation in Alzheimer disease. Arch Neurol 1998; 55: 530-536.
81. Bermejo P, Martin-Aragon S, Benedi J, et-al. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008; 117: 198-202.
82. Zainaghi IA, Forlenza OV, Gattaz WF,. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl) 2007; 192: 547-553.
83. Smirnov A, Trupp A, Henkel AW, et-al. Differential processing and secretion of Abeta peptides and sAPPalpha in human platelets is regulated by thrombin and prostaglandine 2. Neurobiol Aging 2009; 30: 1552-1562.
84. Bellingham SA, Guo BB, Coleman BM, et-al. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 2012; 3: 124.
85. Schneider A, Simons M,. Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res 2013; 352: 33-47.
86. Matsubara E, Shoji M, Murakami T, et-al. Platelet microparticles as carriers of soluble Alzheimer's amyloid beta (sAbeta). Ann N Y Acad Sci 2002; 977: 340-348.
87. Ghiso J, Matsubara E, Koudinov A, et-al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993; 293 (Pt 1): 27-30.
88. Gallo G, Wisniewski T, Choi-Miura NH, et-al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145: 526-530.
89. Narayan P, Orte A, Clarke RW, et-al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1-40) peptide. Nat Struct Mol Biol 2012; 19: 79-83.
90. Benarroch EE,. Lipid rafts, protein scaffolds, and neurologic disease. Neurology 2007; 69: 1635-1639.
91. Schonrock N, Gotz J,. Decoding the non-coding RNAs in Alzheimer's disease. Cell Mol Life Sci 2012; 69: 3543-3559.
92. Boada-Rovira M,. Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease. Rev Neurol 2010; 50 (Suppl 5): S9-18.
93. Matsuoka Y, Saito M, LaFrancois J, et-al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003; 23: 29-33.
94. Mattner F, Schmidt W,. Methods of treating Alzheimer's disease with an apheresis device. United States Patent US 7,935,252 B2. 2011.